scholarly journals Sclerosing Epithelioid Fibrosarcoma: In‐depth review of a genetically heterogeneous tumor

Apmis ◽  
2021 ◽  
Author(s):  
Khaled A. Murshed ◽  
Issam Al‐Bozom ◽  
Adham Ammar
Keyword(s):  
Sclerosing Epithelioid Fibrosarcoma ◽  
Heterogeneous Tumor

scholarly journals Primary sclerosing epithelioid fibrosarcoma presenting as lombosciatic syndrome: Case report and literature review

2021 ◽  
Vol 80 ◽  
pp. 105657
Author(s):  
Karim Khezami ◽  
Ahmed Gharbi ◽  
Mohamed Chabaane ◽  
Mohamed Amine Bennour ◽  
Habib Nouri
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Sclerosing Epithelioid Fibrosarcoma

scholarly journals Sclerosing Epithelioid Fibrosarcoma: Case Presentation and a Systematic Review

2008 ◽  
Vol 466 (6) ◽  
pp. 1485-1491 ◽  
Author(s):  
Christian Ossendorf ◽  
Gabriela M. Studer ◽  
Beata Bode ◽  
Bruno Fuchs
Keyword(s):  
Systematic Review ◽  
Case Presentation ◽  
Sclerosing Epithelioid Fibrosarcoma

Sclerosing epithelioid fibrosarcoma

1996 ◽  
Vol 28 (5) ◽  
pp. 451-456 ◽  
Author(s):  
R. REID ◽  
A. BARRETT ◽  
D.L. HAMBLEN
Keyword(s):  
Sclerosing Epithelioid Fibrosarcoma

scholarly journals Heterogeneous Tumor Subpopulations Cooperate to Drive Invasion

Cell Reports ◽  
2014 ◽  
Vol 8 (3) ◽  
pp. 688-695 ◽  
Author(s):  
Anna Chapman ◽  
Laura Fernandez del Ama ◽  
Jennifer Ferguson ◽  
Jivko Kamarashev ◽  
Claudia Wellbrock ◽  
...  
Keyword(s):  
Heterogeneous Tumor

Case of giant sclerosing epithelioid fibrosarcoma with ossification

2013 ◽  
Vol 40 (8) ◽  
pp. 667-668
Author(s):  
Hiromi Katsue ◽  
Shigeto Matsushita ◽  
Masanao Sakanoue ◽  
Kazuhiro Kawai ◽  
Takuro Kanekura
Keyword(s):  
Sclerosing Epithelioid Fibrosarcoma

scholarly journals The evolving concept of cancer and metastasis stem cells

2012 ◽  
Vol 198 (3) ◽  
pp. 281-293 ◽  
Author(s):  
Irène Baccelli ◽  
Andreas Trumpp
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Tumor Cell ◽  
Dynamic Processes ◽  
Cellular Composition ◽  
Tumor Mass ◽  
Tumor Relapse ◽  
Cancerous Cells ◽  
Heterogeneous Tumor

The cancer stem cell (CSC) concept, which arose more than a decade ago, proposed that tumor growth is sustained by a subpopulation of highly malignant cancerous cells. These cells, termed CSCs, comprise the top of the tumor cell hierarchy and have been isolated from many leukemias and solid tumors. Recent work has discovered that this hierarchy is embedded within a genetically heterogeneous tumor, in which various related but distinct subclones compete within the tumor mass. Thus, genetically distinct CSCs exist on top of each subclone, revealing a highly complex cellular composition of tumors. The CSC concept has therefore evolved to better model the complex and highly dynamic processes of tumorigenesis, tumor relapse, and metastasis.

scholarly journals Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration

2018 ◽  
Author(s):  
Zeya Wang ◽  
Shaolong Cao ◽  
Jeffrey Morris ◽  
Jaeil Ahn ◽  
Rongjie Liu ◽  
...  
Keyword(s):  
Immune Infiltration ◽  
Heterogeneous Tumor

A facial dismasking approach for resection of an infratemporal fossa sclerosing epithelioid fibrosarcoma

2011 ◽  
Vol 81 (12) ◽  
pp. 947-948 ◽  
Author(s):  
Zubair Hasan ◽  
Jonathan R. Clark ◽  
Allan Fowler
Keyword(s):  
Infratemporal Fossa ◽  
Sclerosing Epithelioid Fibrosarcoma

Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites

Oncology ◽  
2021 ◽  
Vol 99 (10) ◽  
pp. 652-658
Author(s):  
Jhe-Cyuan Guo ◽  
Chen-Yuan Lin ◽  
Chia-Chi Lin ◽  
Ta-Chen Huang ◽  
Ming-Yu Lien ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Disease Control ◽  
Immune Checkpoint Inhibitors ◽  
Tumor Response ◽  
Liver Tumors ◽  
Checkpoint Inhibitors ◽  
Recist 1.1 ◽  
Organ Specific ◽  
Heterogeneous Tumor

<b><i>Introduction:</i></b> Heterogeneous tumor response has been reported in cancer patients treated with immune checkpoint inhibitors (ICIs). This study investigated whether the tumor site is associated with the response to ICIs in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC). <b><i>Methods:</i></b> Patients with ESCC who had measurable tumors in the liver, lung, or lymph node (LN) according to the response evaluation criteria in solid tumors (RECIST) 1.1 and received ICIs at 2 medical centers in Taiwan were enrolled. In addition to RECIST 1.1, tumor responses were determined per individual organ basis according to organ-specific criteria modified from RECIST 1.1. Fisher test or χ<sup>2</sup> test was used for statistical analysis. <b><i>Results:</i></b> In total, 37 patients were enrolled. The overall response rate per RECIST 1.1 was 13.5%. Measurable tumors in the LN, lung, and liver were observed in 26, 17, and 13 patients, respectively. The organ-specific response rates were 26.9%, 29.4%, and 15.4% for the LN, lung, and liver tumors, respectively (<i>p</i> = 0.05). The organ-specific disease control rates were 69.2%, 52.9%, and 21.1% for the LN, lung, and liver tumors, respectively (<i>p</i> = 0.024). Five (27.8%) among 18 patients harboring at least 2 involved organs had heterogeneous tumor response. <b><i>Conclusion:</i></b> The response and disease control to ICIs may differ in ESCC tumors located at different metastatic sites, with a lesser likelihood of response and disease control in metastatic liver tumors than in tumors located at the LNs and lung.

scholarly journals A 3D CFD model of the interstitial fluid pressure and drug distribution in heterogeneous tumor nodules during intraperitoneal chemotherapy

Drug Delivery ◽  
2019 ◽  
Vol 26 (1) ◽  
pp. 404-415 ◽  
Author(s):  
Margo Steuperaert ◽  
Charlotte Debbaut ◽  
Charlotte Carlier ◽  
Olivier De Wever ◽  
Benedicte Descamps ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Interstitial Fluid ◽  
Fluid Pressure ◽  
Drug Distribution ◽  
Interstitial Fluid Pressure ◽  
Cfd Model ◽  
Heterogeneous Tumor
Sign in / Sign up

Export Citation Format

Share Document